Pangolin Therapeutics

Pangolin Therapeutics is an early-stage biotech pioneering a novel approach to drug discovery by targeting intrinsically disordered proteins (IDPs), a large class of proteins previously considered undruggable due to their lack of stable structure. The company's proprietary Pangomer platform aims to generate first-in-class therapeutics with disease-modifying potential, initially focusing on Type 2 Diabetes and neurodegeneration. Led by an experienced team and supported by $9.5M in non-dilutive funding, Pangolin is positioned to build a pipeline in high-need therapeutic areas, presenting opportunities for investment and partnership.

Pangomer chemistry platform: a proprietary approach using computational modeling, biophysics, and synthetic chemistry to design therapeutic agents that target intrinsically disordered proteins (IDPs) by mimicking features of peptides and small molecules.

Competition includes other biotechs targeting 'undruggable' proteins via alternative modalities like PROTACs, molecular glues, and stapled peptides. Large pharma are also investing in this space. Pangolin's differentiation lies in its specific chemistry platform (Pangomers) designed for the unique dynamics of IDPs, rather than structured proteins.